Twist Bioscience Corporation (TWST) Expands its Clonal Gene Offering to Include Long and Complex Sequences

Twist Bioscience Corporation (NASDAQ:TWST) is among the Best ARK Stocks

On May 4, Twist Bioscience Corporation (NASDAQ:TWST) expanded its clonal genes portfolio with an early access launch of “Complex Genes,” the company said. The firm added support for longer and more structurally complex DNA sequences.

Complex Genes increases maximum gene length to 7,000 base pairs while allowing acceptance of about 99.5% of clonal gene orders and 99.9% of all DNA products, the company said. It targets sequences historically difficult to produce at scale.

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust said researchers need partners that “consistently deliver genes rapidly at scale and with more complex sequences.” The CEO added that the expansion allows the firm to accept a broader range of designs and accelerate discovery timelines.

Twist Bioscience Corporation (TWST) Expands its Clonal Gene Offering to Include Long and Complex Sequences

The company said the capability supports AI-powered drug discovery and nucleic acid therapeutics, where precise synthesis of complex sequences remains critical.

Twist Bioscience Corporation (NASDAQ:TWST) is developing a patented semiconductor-based synthetic DNA production technique. It operates in the Americas, EMEA, and APAC.

While we acknowledge the risk and potential of TWST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TWST and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1